OMS721

PreclinicalBiologic

OOmeros Corporation

OMS721 is one of 6 biologic programs targeting Thrombotic Microangiopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thrombotic MicroangiopathyActive, not recruiting

Thrombotic MicroangiopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Thrombotic Microangiopathy

#DrugCompanyPhaseTrials

Fabhalta

Novartis

Approved

1 2

Ultomiris

AstraZeneca

Phase 3

2 3

Soliris

AstraZeneca

Phase 3

2 4

N-Acetylcysteine (NAC) Treatment

TThe First Affiliated Hospital of Soochow University

Phase 3

1 5

NM8074

NNovelMed Therapeutics

Phase 2

1 6

OMS721

OOmeros Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

Completed·OOmeros Corporation·Phase 2·NCT02222545·58 enrolled

Dense Deposit Disease1 trial

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Unknown status·OOmeros Corporation·Phase 2·NCT02682407·54 enrolled

Atypical Hemolytic-Uremic Syndrome1 trial

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

Terminated·OOmeros Corporation·Phase 3·NCT03205995·6 enrolled

Nephropathy1 trial

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Terminated·OOmeros Corporation·Phase 3·NCT03608033·360 enrolled

Thrombotic Microangiopathy1 trial

OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy

Available·MMichal Nowicki··NCT02355782

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for OMS721. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OMS721 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OMS721. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Omeros Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: OOmeros Corporation

OMS721

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy1 trial

Dense Deposit Disease1 trial

Atypical Hemolytic-Uremic Syndrome1 trial

Nephropathy1 trial

Thrombotic Microangiopathy1 trial

References

Drug Info

Quick Facts

Related News